Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: Immune checkpoint inhibitor plus chemotherapy as first-line treatment for non-small cell lung cancer with malignant pleural effusion: a retrospective multicenter study

Fig. 3

Subgroup analysis of PFS (3 A) and OS (3B) in patients received chemotherapy and ICI plus chemotherapy. HR: hazard ratio; CI, confidence interval; ECOG PS: Eastern Cooperative Oncology Group Performance Status; PD-L1, programmed cell death-ligand 1; NLR: Neutrophil to Lymphocyte ratio; ICI, immune checkpoint inhibitor; PFS, progression-free survival

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us